Document is current
Any future updates will be listed below
-
Authors
Chandran, M. https://orcid.org/0000-0001-9119-8443
Bhadada, S.K.
Ebeling, P.R.
Gilchrist, N.L.
Khan, A.H.
Halbout, P.
Lekamwasam, S.
Lyubomirsky, G.
Mitchell, P.J.
Nguyen, T.V.
Tiu, K.L.
,
-
Funding
Funding for this research was provided by:
Amgen Asia
- License Information
-
More Information
Article History
Received: 15 April 2020
Accepted: 4 June 2020
First Online: 19 June 2020
Compliance with ethical standards
:
: The opinions and activities of APCO are not influenced by Amgen, nor did Amgen have any role in the writing of this opinion piece.
: Dr. Manju Chandran has received honoraria for lectures and sponsorships for conferences from Eli Lilly and Amgen.Professor Peter Ebeling has research funding from Amgen, Eli-Lilly, Novartis and Alexion and has received honoraria from Amgen and Alexion.Paul Mitchell (PM) has undertaken consultancy for governments, national and international osteoporosis societies, healthcare professional organisations and private sector companies relating to systematic approaches to fragility fracture care and prevention since 2005. PM serves as APCO Project Manager on a paid consultancy basis.Professor Tuan Nguyen has received grant support from Amgen and honoraria for lectures and conference engagements from Novartis, MSD, Amgen and Bridge Health Care.Drs Sanjay Bhadada, Nigel Gilchrist, Aysha Habib Khan, Philippe Halbout, Sarath Lekamwasam, Greg Lyubomirsky and Kwok Leung Tiu declare that they have no conflict of interest.
